Replimune Group Inc Share Price Today: Live Updates & Key Insights

Replimune Group Inc share price today is $7, up 1.31%. The stock opened at $6.87 against the previous close of $6.89, with an intraday high of $7.165 and low of $6.82.

Replimune Group Inc Share Price Chart

Replimune Group Inc

us-stock
To Invest in {{usstockname}}
us-stock

Replimune Group Inc Share Price Performance

$7 0.0131(1.31%) REPL at 23 Mar 2026 03:00 PM Biotechnology
Lowest Today 6.82
Highest Today 7.165
Today’s Open 6.87
Prev. Close 6.89
52 Week High 13.24
52 Week Low 2.68
Day’s Range: Low 6.82 High 7.165
52-Week Range: Low 2.68 High 13.24
1 day return -
1 Week return -4.76
1 month return -16.56
3 month return -29.47
6 month return +113.74
1 year return -36.59
3 year return -62.92
5 year return -79.6
10 year return -

Replimune Group Inc Institutional Holdings

Baker Bros Advisors LP 13.38

T. Rowe Price Associates, Inc. 10.06

RTW INVESTMENTS, LLC 8.65

BlackRock Inc 6.99

FCPM III SERVICES BV 5.04

Vanguard Group Inc 4.57

Point72 Asset Management, L.P. 4.40

TANG CAPITAL MANAGEMENT LLC 4.12

FMR Inc 3.61

State Street Corp 3.54

Readystate Asset Management LP 3.17

D. E. Shaw & Co LP 3.12

Fidelity Select Biotechnology 2.99

US Small-Cap Growth II Equity Comp 2.95

T. Rowe Price New Horizons 2.95

State Street® SPDR® S&P® Biotech ETF 2.84

Erste Asset Management GmbH 2.57

Vanguard Total Stock Mkt Idx Inv 2.24

Adage Capital Partners Gp LLC 2.19

Geode Capital Management, LLC 2.12

iShares Russell 2000 ETF 2.07

T. Rowe Price Integrated US SmCapGrEq 1.94

T. Rowe Price Integrated US Sm Gr Eq 1.94

T. Rowe Price Health Sciences 1.84

COMMODORE CAPITAL LP 1.73

Rosalind Advisors, Inc. 1.71

Morgan Stanley - Brokerage Accounts 1.67

The Toronto-Dominion Bank 1.66

ADAR1 Capital Management LLC 1.50

T. Rowe Price New Horizons Tr-A 1.25

Vanguard Institutional Extnd Mkt Idx Tr 0.94

Fidelity Small Cap Index 0.82

iShares Russell 2000 Value ETF 0.73

iShares Biotechnology ETF 0.65

Fidelity Enhanced Small Cap ETF 0.57

State St Russell Sm/Mid Cp® Indx SL Cl I 0.47

Fidelity Extended Market Index 0.46

Schwab US Small-Cap ETF™ 0.42

Vanguard Russell 2000 ETF 0.40

ERSTE STOCK BIOTEC EUR R01 A 0.39

Replimune Group Inc Market Status

Strong Buy: 3

Buy: 5

Hold: 0

Sell: 0

Strong Sell: 0

Replimune Group Inc Fundamentals

Market Cap 576.36 M

PB Ratio 2.7022

PE Ratio 0.0

Enterprise Value 383.57 M

Total Assets 551.33 M

Volume 2447119

Replimune Group Inc Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY25:-3502000 -3.5M, FY24:-2655000 -2.7M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-247297000 -247.3M, FY24:-215794000 -215.8M, FY23:-174284000 -174.3M, FY22:-117646000 -117.6M, FY21:-83265000 -83.3M

Quarterly Revenue Q4/2025:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:1472000 1.5M, Q4/2024:0 0.0M

Quarterly Profit Q4/2025:-1649000 -1.6M, Q3/2025:-1640000 -1.6M, Q2/2025:-1665000 -1.7M, Q1/2025:-848000 -0.8M, Q4/2024:null 0.0M

Quarterly Net worth Q4/2025:-70930000 -70.9M, Q3/2025:-83100000 -83.1M, Q2/2025:-86693000 -86.7M, Q1/2025:-74130000 -74.1M, Q4/2024:-66340000 -66.3M

About Replimune Group Inc & investment objective

Company Information Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Organisation Biotechnology

Employees 479

Industry Biotechnology

CEO Dr. Sushil Patel Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Replimune Group Inc FAQs

What is the share price of Replimune Group Inc today?

The current share price of Replimune Group Inc is $7.

Can I buy Replimune Group Inc shares in India?

Yes, Indian investors can buy Replimune Group Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Replimune Group Inc shares in India?

You can easily invest in Replimune Group Inc shares from India by:

Can I buy fractional shares of Replimune Group Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Replimune Group Inc?

Replimune Group Inc has a market cap of $576.36 M.

In which sector does Replimune Group Inc belong?

Replimune Group Inc operates in the Biotechnology sector.

What documents are required to invest in Replimune Group Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Replimune Group Inc?

The PE ratio of Replimune Group Inc is N/A and the PB ratio is 2.70.